Table II.
Type of treatment response and the relationship to EGFR mutation status
| Gefitinib, no. (%) | Erlotinib, no. (%) | p-valuea | |
|---|---|---|---|
| With activating mutations | 0.277 | ||
| Partial response | 48 (51.1) | 30 (57.7) | |
| Stable disease | 35 (37.2) | 13 (25) | |
| Progressive disease | 11 (11.7) | 9 (17.3) | |
| Without activating mutations | 0.446 | ||
| Partial response | 4 (13.3) | 12 (25) | 0.064b |
| Stable disease | 11 (36.7) | 14 (29.2) | |
| Progressive disease | 15 (50) | 22 (45.8) |
a
Pearson’s two-sided Chi-square test;
b
when partial response or no partial response was compared between the two agents. EGFR, epidermal growth factor receptor.